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1. Abstract 
Introduction: Transjugular intrahepatic porto-systemic shunt (TIPS) is an accepted 
indication for treating refractory ascites. Different models have been proposed for the 
prediction of survival after TIPS; aim of present study was to evaluate the factors 
associated with mortality after TIPS for refractory ascites. 
Methods: Seventy-three consecutive patients undergoing a TIPS for refractory ascites in 
our centre between 2003 and 2008, were prospectively recorded in a database ad were 
the  subject of the study. Mean follow-up was 17±2 months. Forty patients were awaiting 
liver transplantation (LT) and 12 (16.4%) underwent LT during follow-up. 
Results: Mean MELD at the moment of TIPS was 15.7±5.3. Overall mortality was 23.3% 
(n=17) with a mean survival after TIPS of 17±14 months. MELD score (B=0.161, 
p=0.042), AST (B= 0.020, p=0.090) and pre-TIPS HVPG (B=0.016, p=0.093) were 
independent predictors of overall mortality. On multivariate analysis MELD (B=0.419, 
p=0.018) and pre-TIPS HVPG (B=0.223, p=0.060) independently predicted 1 year 
survival. Patients were stratified into categories of death risk, using ROC curves for the 
variables MELD and HVPG. Patients with MELD<10 had a low probability of death after 
TIPS (n=6, 16% mortality); patients with HVPG <16 mmHg (n=6) had no mortality. 
Maximum risk of death was found in patients with MELD score ≥19 (n=16, 31% mortality) 
and in those with HVPG ≥25 mmHg (n=27, 26% mortality). 
Conclusions: TIPS increases overall survival in patients with refractory ascites. Liver 
function (assessed by MELD), necroinflammation (AST) and portal hypertension (HVPG) 
are independent predictors of survival; patients with MELD>19 and HVPG>25 mmHg are 
at highest risk of death after TIPS. 
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2. Introduction 
Refractory ascites is a severe complication of cirrhosis with a 1 year survival of about 
50% (1). Transjugular intrahepatic porto-systemic shunt (TIPS) is an accepted indication 
for the treatment of refractory ascites and a valid alternative to large volume paracentesis 
(LVP) (2, 3). Survival after TIPS placement for refractory ascites has been suggested to 
be worse than for variceal bleeding (4, 5). Although this finding has not been confirmed 
by larger studies, survival after TIPS has been related to the degree of hepatic 
dysfunction expressed mainly by bilirubin, aminotransferases and creatinine levels, and 
also to age and urgent indication to the procedure (2, 4-7). 
Different models have been proposed for the prediction of survival after TIPS; these 
included the Mayo score, later modified into the MELD score (Model for End stage Liver 
Disease), and others (4, 8-13). These scoring systems, however, are based on 
populations of patients with various indications to TIPS, mainly variceal bleeding, and 
have not been validated in a cohort of patient with refractory ascites alone. 
Aim of this study was to evaluate the factors associated with mortality after TIPS 
positioning for refractory ascites in our centre. 
 
3.0 Materials and Methods 
All consecutive patients undergoing a TIPS procedure in our centre were prospectively 
recorded in a database; patients who underwent TIPS for refractory ascites, defined as 
lack of response to a low sodium diet and adequate doses of diuretics (14) requiring 
repeated LVP in S. Orsola-Malpighi Hospital, between February 2003 and January 2008, 
were identified from the database and were the  subject of the present study. Mean 
follow-up was 17±2 months. 
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For all patients, the following data were collected in a database: age, sex, etiology of liver 
disease, HVPG before TIPS, presence and grade of encephalopathy before and after the 
procedure, standard blood test (including INR, creatinine, electrolytes, transaminases), 
early and late complications of the procedure, number of revisions performed, survival, 
presence in the waiting list for liver transplantation (LT) and LT. For all patients the Mayo 
score (12) and MELD score were calculated. All hematological tests were measured 
using conventional test at the Central Laboratory of S. Orsola-Malpighi Hospital. Budd-
Chiari syndrome was an exclusion criterion for the inclusion in the database regarding 
the present paper. All patients gave their written informed consent to the TIPS 
procedure. This study followed the Declaration of Helsinki principles.  
 
3.1 Statistical analysis 
Kaplan-Meier curves were used to analyze long term survival. Cox proportional-hazards 
regression model was performed to assess risk factors for mortality, and factors 
significant at univariate analysis were entered in a multivariate model to identify 
independent predictors of mortality. ROC curves were used to define the best cut-off of 
continuous variables for mortality prediction. Patients who underwent orthotopic liver 
transplantation were censored at the moment of OLT. P values < 0.05 were considered 
statistically significant. All data analyses were performed using Statistical Package for 
Social Science (SPSS), version 15. 
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3.2 HVPG measurement and TIPS positioning 
The TIPS procedure was performed in the angiographic suite with the patients deeply 
sedated. The right jugular vein was punctured under sonographic guidance and a first 
catheter was advanced to reach the right atrium and then the hepatic veins: free and 
wedged hepatic venous pressures were then measured by a balloon catheter (7F 
balloon-tipped catheter, OB-Medi-Tech, Boston Scientific Cork Ltd., Cork, Ireland), and 
hepatic venous pressure gradient (HVPG) was calculated as the difference between 
wedge and free pressures. A standard RUPS-100 Rosch-Uchida transjugular liver 
access set (Cook®) was used for TIPS creation (i.e. the shunt between right portal 
branch and the hepatic vein). In most patients, the sagittal hepatic vein and the right 
portal vein were used to create the track, under fluoroscopic and/or ultrasound (US) 
guidance. After puncture of the portal branch, a portal venogram was obtained to assess 
the track length and in order to exclude the presence of portal vein thrombosis or 
enlarged gastric veins. Then a measurement of portal vein pressure was obtained. 
In all cases self-expandable metallic uncovered stent (Wallstent 12 mm in diameter and 
6 to 9 mm in length) were positioned and subsequently dilated through high-pressure 
angioplasty balloon catheters of equivalent size to the nominal diameters of the stent. At 
the end of the procedure a portography was performed to verify the shunt patency, the 
direction of the portal flow and to exclude the persistent filling of varices. In patients with 
variceal persistent perfusion, a selective coil embolization of left gastric or short gastric 
veins varices was performed. Portal pressure and right atrial pressure after TIPS 
positioning were measured, and porto-atrial gradient was calculated.  After the 
procedure, all patients underwent clinical follow-up and stent patency was monitored by 
ECD-US before discharge and by MDCT one month later. 
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4.0 Results 
Seventy-three patients (67% males) were included in the study. Table 1 summarizes the 
main characteristics of patients at inclusion. Median age at the time of TIPS creation was 
59 years (range, 34-76 y). Mean MELD score at the moment of TIPS positioning was 
15.7±5.3. Forty patients were in the waiting list for LT and 12 (16.4%) underwent LT 
during follow-up. Thirty-three patients were not awaiting LT; 2 of them were performing 
the work-up for inclusion in the waiting list, the remaining were excluded from LT for the 
following reasons: 18 for age over 67 years, 2 for hepatocellular carcinoma (HCC) 
exceeding Milan criteria, and 11 for low MELD score (according to the statements of our 
transplant centre establishing that the minimum score needed for inclusion in the waiting 
list is 13). 
 
4.1 Overall survival 
Overall mortality rate was 23.3% (n=17) with a mean survival after TIPS of 17±14 
months.  At univariate analysis (Table 2), increasing values of MELD score, Mayo Risk 
Score, AST and ALT, bilirubin, INR and pre-TIPS HVPG significantly increased the risk 
of death on follow-up. In our population age, gender, etiology of liver disease, creatinine 
and sodium were not associated to mortality (Table 2).  
Given the limited number of events (n=17), and given the wide use of MELD score in 
clinical practice, which includes creatinine, INR and bilirubin, we chose to consider in the 
multivariate analysis the following variables: MELD score, AST, diastolic arterial blood 
pressure and HVPG. The model identified as independent predictors of overall mortality 
the following variables:  MELD score (B=0.161, p=0.042), AST (B= 0.020, p=0.090) and 
pre-TIPS HVPG (B=0.016, p=0.093).  
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By using the previously identified risk threshold for TIPS, namely a MELD score below or 
higher than 18 (13), in the present series, patients with a high (>18) MELD score had a 
poorer OLT-free survival after TIPS placement than low risk patients (MELD ≤18; 
p=0.002).  
 
4.2 Three months survival  
Six patients died during the first three months after TIPS, and 7 patients were 
transplanted in the same period.  
Patients with poor short-term prognosis differed from survivors at 3 months for the 
following variables: bilirubin, AST, ALT and MELD score. On multivariate analysis high 
AST (B=0.065, p=0.136) and bilirubin (B=0.606, p=0.046) values independently 
predicted a <3-months survival.  
 
4.3 One year survival 
Thirteen patients died during the first year after TIPS and 12 underwent OLT.  
Survivors at 1 year had lower values of MELD score, Mayo Risk Score, bilirubin, INR and 
HVPG at the time of TIPS placement as compared with patients who died on follow-up. 
On multivariate analysis MELD score (B=0.419, p=0.018) and pre-TIPS HVPG (B=0.223, 
p=0.060) independently predicted 1 year survival.  
However, the added value of considering pre-TIPS HVPG in adjunct to MELD score 
alone was minimal since no significant difference in the discriminative ability of the model 
was observed (Table 3). 
In order to easily stratify patients into categories of death risk after TIPS, we calculated 
the ROC curves for the two variables selected by the model for 1 year survival. We then 
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selected from the ROC curves the best cut-offs to identify the highest and lowest risk of 
death in our population (Figure 1 and 2).  
The AUROC were as follows: MELD score: 0.754, p=0.001; HVPG: 0.664, p=0.027.  
Therefore, based on these results,  patients could be classified into three groups of risk 
according to MELD and HVPG: low risk (MELD <10, HVPG <16 mmHg), intermediate 
risk (MELD 10-19, HVPG 16-25 mmHg) and high risk (MELD >19, HVPG 25 mmHg).  
According to this classification patients with MELD score <10 had a low probability of 
death after TIPS (n=6, 16% mortality); patients with HVPG <16 mmHg (n=6) had no 
mortality in this study. Maximum risk of death was found in patients with MELD score ≥19 
(n=16, 31% mortality) and in those with HVPG ≥25 mmHg (n=27, 26% mortality). 
 
4.4 Ascites and need for TIPS revision 
Within 1 year from TIPS placement, 40 (54%) patients had a resolution of ascites or a 
significant improvement of ascites control with no need of paracentesis. In the remaining 
46%, no significant improvement was obtained.  
Forty patients (52.3%) underwent minor TIPS revision during the follow-up due to TIPS 
dysfunction, clinically detected for the relapse of ascites or for the ultrasonografic (US) 
finding of hepatofugal flow in the portal vein during the periodical US follow-up. 
Additionally, 2 patients required TIPS reduction for the onset of severe early 
encephalopathy and a severe liver dysfunction. 
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5. Discussion 
In our population of patients with refractory ascites, TIPS placement led to a long survival 
in the majority of patients. Survival rates obtained in our study are similar to the 
previously reported results in a similar setting of patients being 65% after 1 year (2, 15). 
Liver function (assessed by MELD score), necroinflammation (assessed by AST) and 
portal hypertension (assessed by HVPG) are independent predictors of mortality after 
TIPS. However, necroinflammation holds a predictive value in the short-term period, 
while liver function and portal hypertension help stratifying patients in the middle-long 
term period. In the univariate analysis decreasing values of diastolic blood pressure and 
mean arterial pressure showed a trend towards increasing risk of death: these 
parameters are the expression of the hyperdynamic syndrome due to portal 
hypertension. Interestingly, HVPG is one of the independent factors associated to 
mortality after TIPS in this study, thus confirming the impact of the severity of portal 
hypertension on the prognosis of cirrhotic patients undergoing TIPS.  
However, the strongest independent predictor of mortality in our series was MELD score. 
This was not unexpected, since MELD was originally designed to predict mortality after 
TIPS (13).  Contrarily to other studies, in our population sodium level and creatinine were 
not associated to mortality (2, 16, 17). This may depend from the clinical protocols 
applied in our Hospital, which include the routine infusion of human albumin in cirrhotic 
patients with refractory ascites (18) with a beneficial effect on renal function.  
The main original result of the present study is the finding of the independent prognostic 
value of HVPG on survival after TIPS. However, HVPG was inferior to MELD in the 
prediction of mortality, as shown by the area under the ROC curve; moreover the 
addition of HVPG to MELD did not significantly increase the precision of the risk model 
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only based on the MELD score. The combination of the two parameters, from a practical 
point of view, allowed us to stratify patients into three risk categories. Patients at higher 
risk of death after TIPS were those with high MELD (>19) and high HVPG (>25 mmHg). 
The ideal patients were the ones with relatively preserved liver function (MELD<10) and 
HVPG<16 mmHg.  
Considering that TIPS allows a good survival and that death after TIPS is related to 
MELD and HVPG, our results suggest that, in order to obtain the best outcome, referral 
to TIPS for refractory ascites should be done as early as possible, when the liver function 
is not too impaired and the portal pressure is still not extremely high. For patients with 
advanced liver disease (MELD >19) and high HVPG (>25 mmHg), the risk-benefit 
evaluation might suggest to perform TIPS only in patients awaiting LT, as mortality is > 
25% after 1 year. 
A limitation of the present study is its retrospective design. Nonetheless, we included and 
analyzed all the consecutive patients who underwent TIPS for cirrhosis and refractory 
ascites in our Center. The present series includes only patient treated with bare stents 
for the TIPS creation and none treated with PTFE-covered stents positioning. Although it 
has been suggested that PTFE-covered stent may improve the outcome of patients 
treated with TIPS, due to a reduction of stent dysfunctions and to improved long term 
primary stent patency (19-22), the survival rate of patients in the present study only 
employing bare stents is comparable to that of previous series using covered stents [19-
22] as well as the TIPS patency rates, with cumulative primary and secondary patency 
rates respectively 79% and 99% at a mean of 30 months, similarly to those reported by 
other authors (23) 
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In conclusion, our study confirms that TIPS increases overall survival in patients with 
refractory ascites. Liver function (assessed by MELD), necroinflammation (assessed by 
AST) and portal hypertension (assessed by HVPG) are independent predictors of 
survival; the highest mortality after TIPS is observed in those patients presenting with 
MELD>19 and HVPG>25 mmHg, therefore suggesting that the referral for TIPS in 
presence of refractory ascites should be limited to the patients in the waiting list for liver 
transplantation. 
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Table 1:  
Demographic, biochemical and hemodynamic features in patients undergoing elective 
transjugular intrahepatic portosystemic shunt for refractory ascites included in the 
present study (n=73). 
 
 n % Mean (SD) 
Demographic 
Age (y)   57 (10) 
            Gender (males) 52 71.2  
Cause of cirrhosis 
Virus related 39 53.5  
                         Alcoholic 24 32.8  
   Cryptogenic 6 8.3  
                        Cholestatic 2 2.7  
Other 2 2.7  
Biochemical 
Serum bilirubin (mg/dl)   2.5 (2.4) 
Serum creatinine (mg/dl)   1.22 (0.52) 
INR    1.45 (0.26) 
   AST (U/ml)   44 (22) 
            ALT (U/ml)   27 (15) 
            Serum Na (mEq/L)   134 (5) 
            MELD Score   15.7 (5.3) 
            Mayo risk score   1.2 (0.6) 
Hemodynamic    
            SBP (mmHg)   109 (12) 
   DBP (mmHg)   67 (8) 
            MAP (mmHg)   81 (9) 
            FHVP (mmHg)   9.7 (5.2) 
            WHVP (mmHg)   32.6 (7.6) 
            HVPG (mmHg)   23.1 (6.2) 
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Table 2: 
Univariate analysis of risk factors for death (overall survival) among included patients 
undergoing TIPS for refractory ascites (Cox proportional hazards regression model). 
Parameter Regression coefficient 
Standard 
error p 
Sex (male) 0.111 0.443 0.801 
Age 
−0.016 0.021 0.441 
Cause of cirrhosis 
−0.015 0.105 0.885 
Aetiology (HCV) 
−0.119 0.393 0.761 
Bilirubin 0.243 0.068 <0.0001 
Creatinine 
−0.030 0.473 0.950 
INR 2.403 0.875 0.006 
AST 0.028 0.010 0.004 
ALT 0.038 0.014 0.009 
Na 
−0.059 0.046 0.204 
MELD score 0.198 0.042 <0.0001 
Mayo risk score 1.288 0.455 0.005 
SBP 
−0.022 0.021 0.302 
DBP 
−0.065 0.036 0.070 
MAP 
−0.056 0.032 0.079 
FHVP 
−0.026 0.045 0.565 
WHVP 0.047 0.024 0.055 
HVPG 0.078 0.031 0.012 
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Table 3: 
Overall C-Statistic for Coxs Predictive Model in the prediction of 1-year survival after 
TIPS in the studied population. 
 
Variables in the Model  Overall C-Statistic 95% CI 
MELD 0.73 0.590.87 
MELD + HVPG 0.74   0.580.84 
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Figure 1 
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Figure 2 
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